Article

OptiMedica sells retina, glaucoma assets to Topcon

OptiMedica Corp. is selling its retina and glaucoma assets to Topcon Corp. to focus exclusively on its cataract-related business.

Santa Clara, CA-OptiMedica Corp. is selling its retina and glaucoma assets to Topcon Corp. to focus exclusively on its cataract-related business, including the global market launch of a laser cataract surgery system and cataract-focused research and development.

The company expects to launch its laser cataract surgery system in the United States and in international markets in 2011.

“Topcon has been an outstanding distribution partner for the pattern scan laser photocoagulator [PASCAL] in several major markets, so we are confident that they are ideally suited to advancing [the photocoagulator] in the global marketplace,” said Mark J. Forchette, OptiMedica president and chief executive officer.

Hiroshi Fukuzawa, general manager, eye care business unit, Topcon, said the acquisition is the largest in the company’s medical division.

“Given the aging population and continued growth in diabetic and age-related eye disease, the therapeutic laser market continues to be a major opportunity in ophthalmology,” Fukuzawa said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.